Maravai LifeSciences Holdings, Inc.
MRVI · NASDAQ
Financial statements
Annual and quarterly income, balance-sheet, cash-flow and key-statistics data.
Income statement
| Period | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2022 FY | 883.00M | 714.04M | 574.22M | 220.21M | 1.67 |
| 2023 FY | 288.95M | 140.20M | -31.65M | -119.03M | -0.90 |
| 2024 FY | 259.19M | 108.31M | -235.62M | -144.85M | -1.05 |
| 2025 FY | 185.74M | 33.39M | -6.74M | -130.77M | -0.91 |
Balance sheet
| Period | Total assets | Liabilities | Cash | Debt | Equity |
|---|---|---|---|---|---|
| 2022 FY | 2.28B | 1.38B | 632.14M | 585.26M | 545.22M |
| 2023 FY | 1.49B | 697.57M | 574.96M | 610.97M | 416.75M |
| 2024 FY | 1.01B | 431.04M | 322.40M | 376.69M | 325.29M |
| 2025 FY | 770.58M | 397.87M | 216.89M | 35.58M | 212.38M |
Cash flow
| Period | Operating cash flow | Capital expenditure | Free cash flow | Dividends paid | Net cash change |
|---|---|---|---|---|---|
| 2022 FY | 535.98M | -17.09M | 518.89M | — | 80.87M |
| 2023 FY | 126.22M | -65.55M | 60.67M | — | -57.18M |
| 2024 FY | 7.47M | -29.66M | -22.19M | — | -252.56M |
| 2025 FY | -57.57M | -13.15M | -70.72M | — | -105.51M |
Key statistics
| Period | Market cap | Enterprise value | P/E | Price / sales | Debt / equity |
|---|---|---|---|---|---|
| 2022 FY | 3.58B | 3.54B | — | — | — |
| 2023 FY | 1.64B | 1.68B | — | — | — |
| 2024 FY | 1.43B | 1.49B | — | — | — |
| 2025 FY | 897.59M | 716.28M | — | — | — |
| 2026-12-31 | — | — | — | — | — |
| 2027-12-31 | — | — | — | — | — |
| 2028-12-31 | — | — | — | — | — |
Income statement
| Period | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2025 Q2 | 47.40M | 7.77M | -66.28M | -39.59M | -0.27 |
| 2025 Q3 | 41.63M | 5.66M | 115.44M | -25.56M | -0.18 |
| 2025 Q4 | 49.87M | 12.24M | -6.74M | -35.68M | -0.25 |
| 2026 Q1 | 65.84M | 33.70M | 2.47M | -3.73M | -0.03 |
Balance sheet
| Period | Total assets | Liabilities | Cash | Debt | Equity |
|---|---|---|---|---|---|
| 2025 Q2 | 896.97M | 428.98M | 269.91M | 363.59M | 265.86M |
| 2025 Q3 | 849.19M | 417.33M | 243.57M | 35.85M | 245.44M |
| 2025 Q4 | 770.58M | 397.87M | 216.89M | 35.58M | 212.38M |
| 2026 Q1 | 713.22M | 344.13M | 165.92M | 270.88M | 211.56M |
Cash flow
| Period | Operating cash flow | Capital expenditure | Free cash flow | Dividends paid | Net cash change |
|---|---|---|---|---|---|
| 2025 Q2 | -10.27M | -2.87M | -13.14M | — | -15.15M |
| 2025 Q3 | -15.15M | -2.93M | -18.08M | — | -26.33M |
| 2025 Q4 | -22.77M | -2.11M | -24.88M | — | -26.68M |
| 2026 Q1 | 8.67M | -4.44M | 4.23M | — | -50.97M |
Key statistics
| Period | Market cap | Enterprise value | P/E | Price / sales | Debt / equity |
|---|---|---|---|---|---|
| 2025 Q2 | 661.75M | 755.43M | — | — | — |
| 2025 Q3 | 790.50M | 582.77M | — | — | — |
| 2025 Q4 | 897.59M | 716.28M | — | — | — |
| 2026 Q1 | 788.87M | 893.83M | — | — | — |
| 2026-06-30 | — | — | — | — | — |
| 2026-09-30 | — | — | — | — | — |
| 2026-12-31 | — | — | — | — | — |